Latest Conference Articles

A third review of TrueTear from Allergan showed the device is safe and efficacious in patients with dry eye.

A review of over 13,000 newly-diagnosed DME patients found that about 75% received no treatment in the first 28 days since diagnosis.

Vision loss patients may be 3 times as likely to suffer from major depressive symptoms than the general population.

The demand for diabetic-based health care is growing, and the future of imaging and treatment must follow guidelines.

The study compared bevacizumab, ranibizumab, and aflibercept for nAMD patients' eyes.

Studies based on data from the world's largest clinical specialty database corrected commonly-perceived trends in ophthalmology.

The grant will provide $35,000 to 6 inidivual researchers, who will use the 41 million-plus patient database IRIS Registry.

Luxturna, an injection therapy, helped genetic vision-loss patients navigate mazes in a phase 3 trial.

The biologic agent has shown efficacy in reducing asthma exacerbations and improving patient quality of life.

Robert Zivadinov, MD, discussed how the results of the TOPIC study will impact clinical practice for those specializing in mutliple sclerosis, and what doctors should look for while caring for patients with MS.

Gordon L. Yung, MD, FCCP, explains the right patient perspective of the antifibrotic therapy.

Ruth Ann Marrie, MD, PhD, FRCP, discussed what it's like to treat patients with multiple sclerosis from a team-based approach, as well as what needs to be done to address the issues faced by patients with MS that also have comorbidities.

Robert Zivadinov, MD, discussed the remaining question about Aubagio's mechanism of action after collecting data from the TOPIC study.

Almost 500 patients were split into 4 dosing groups for JZP-110.

Researchers studied recently-referred COPD patients and what attributes put them at risk for poor inhaler device technique.

Attendees at MS Paris 2017 discussed the biggest unmet needs in treating multiple sclerosis.

Many of the symptoms of VTE are normal during pregnancy, and it's difficult to find a suitable population to test out new diagnostic and therapeutic methods.

There's a medical emergency in one in every 604 flights. Here's what doctors need to know so they can handle them appropriately.

John Corboy, MD, discussed how there is a lack of knowledge on when and why to stop using disease-modifying therapies with MS patients.

Two consecutive CHEST studies showed combination therapy's expanding portfolio.

Commercial drivers are very unlikely to admit to symptoms that might result in loss of working time and money. That's where their primary care physicians come in.

Data from the TEMSO study has shown that Aubagio can significantly improve PASAT-3 scores.

Telemedicine is extraordinarily promising for patients and practitioners, but there are lingering challenges that are keeping it from reaching its full potential.

Telemedicine is more than just a trend in medicine – it's one of the most potent tools available to health systems and patients alike.

Regeneron and Sanofi released more positive phase 3 trial results, a day following phase 2b results were shared at CHEST.

Robert Zivadinov, MD, spoke about the results of the TOPIC study and how cortical gray matter atrophy is associated with conversion to clinically definite MS.

John Corboy, MD, discussed the challenges of collecting data about how stopping disease-modifying therapies affects patients with MS.

Clinicians now have pharmacologic and nonpharmacologic treatments that can be very effective for the common condition.

Physicians who do not comply with MACRA will face 4% penalties in 2019.

There's a perfect storm brewing that makes telemedicine an inevitability in the management of conditions like asthma and COPD.